Redhill BioPharma Nabs Mexican Approval for Phase 2/3 Trial of Yeliva for COVID-19
Mexico’s drug regulators have approved RedHill Biopharma’s planned phase 2/3 trial of Yeliva (opaganib) in hospitalized COVID-19 patients with pneumonia.
The study aims to enroll 270 patients who will either receive Yeliva or a placebo along with the standard of care. It will assess the proportion of patients requiring intubation and mechanical ventilation by day 14.
The global study has previously been approved in Russia and the UK, and is awaiting approval in Italy and Brazil.